Stock TKD TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Takeda Pharmaceutical Company Limited Wiener Boerse

Equities

TKD

JP3463000004

Real-time Estimate Tradegate
Other stock markets
 08:14:33 2024-06-21 am EDT 		5-day change 1st Jan Change
23.76 EUR -3.32% Intraday chart for Takeda Pharmaceutical Company Limited +0.53% -4.80%
08:50am Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes MT
07:47am Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India RE

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company appears to be poorly valued given its net asset value.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • The opinion of analysts covering the stock has improved over the past four months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • One of the major weak points of the company is its financial situation.
  • With an expected P/E ratio at 45.24 and 69.41 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TAKEDA PHARMACEUTICAL COMPANY LIMITED Stock Takeda Pharmaceutical Company Limited
-4.80% 39.77B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.99% 798B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.72% 356B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.94% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+11.07% 304B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.63% 244B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.58% 227B
A+
NOVARTIS AG Stock Novartis AG
+10.97% 216B
B-
AMGEN INC. Stock Amgen Inc.
+7.59% 166B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.65% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. TKD Stock
  5. Ratings Takeda Pharmaceutical Company Limited